How many Liraglutide clinical trials are there?

408 Liraglutide clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 11 are actively recruiting participants. 306 are marked completed.

Are Liraglutide clinical trials recruiting in 2026?

Yes — 11 Liraglutide trials are actively recruiting in 2026, with 5 U.S. sites across 5 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Liraglutide being studied for?

Liraglutide is being studied for Diabetes, Diabetes Mellitus, Type 2, Obesity, Type 2 Diabetes, Type 2 Diabetes Mellitus and 173 more. The trials are grouped by indication on this page.

What phase is Liraglutide in?

Liraglutide clinical trials span 109 Phase 4, 101 Phase 3, 55 Phase 2, 60 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Liraglutide clinical trials?

The lead sponsor across the most Liraglutide trials is Novo Nordisk A/S, with 187 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Liraglutide Clinical Trials (2026): 408 Studies for Diabetes & Diabetes Mellitus, Type 2

Creator: Hipa.ai Research
Published: 2026-05-08T18:57:00.799Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

408 Liraglutide clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 104 indications (including Diabetes & Diabetes Mellitus, Type 2) and 788,227 total planned enrollment. 101 Phase 3 Liraglutide trials and 55 Phase 2, 109 Phase 4 are listed. 14 Liraglutide clinical trials are actively recruiting at 5 U.S. sites across 5 states. Most recent activity: NCT06742710 (Dec 2029).

Where to Participate: All Liraglutide Trial Sites in the U.S. (5 sites across 5 states)

Every actively recruiting Liraglutidetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
CA	Altasciences Clinical LA, Inc.	Cypress90630	NCT07225816	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT06976619	Map
NY	Neuroendocrine Unit and Pituitary Center, Columbia University Irving Medical Center	New York10032	NCT05681299	Map
OH	Cincinnati Children's Hospital Medical Center	Cincinnati45229	NCT07029009	Map
VA	University of Virginia	Charlottesville22906	NCT04575844	Map

Liraglutide clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	completed	terminated	withdrawn	suspended	not yet recruiting	unknown	Total
Early P1			2	1		1			4
P1	1		56	1	1			1	60
P1/P2	1		4					1	6
P2	2		40	4	4			5	55
P2/P3			4		1			1	6
P3	1	1	82	4	2		1	10	101
P4	5	2	73	8	3		2	16	109
N/A	1	5	45		3			13	67

Recruiting Liraglutide clinical trials (14)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT06742710	LITOPLiraglutide Treatment in Obese Infertile PCOS Women	P4	PCOS	890	May 2025
NCT06976619	The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes	P2	Type 1 Diabetes	60	Oct 2025
NCT07244003	MESSAGEEfficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control	P4	T2DM (Type 2 Diabetes Mellitus)	430	Mar 2025
NCT05681299	Effects of GH and Lirglutide on AgRP	P4	Healthy	40	May 2023
NCT06361238	Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery	P3	Delirium, Postoperative	260	Nov 2024
NCT06865365	Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone	P4	Obesity, Adolescent	72	May 2025
NCT07301437	RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.	P4	Overweight and Obese Adults	120	May 2026
NCT06836284	The Evira Study: Additional Support During Obesity Treatment	N/A	Childhood Obesity	40	Feb 2026
NCT04575844	ZQL008Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome	P4	Metabolic Syndrome	80	Nov 2020
NCT07029009	MODYLiraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)	P2	Maturity Onset Diabetes of the Young	50	May 2025
NCT07225816	Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)	P1	Obesity	75	Nov 2025
NCT05268237	Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus	P1/P2	Diabete Type 2	15	Apr 2023
NCT06559722	A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes	P3	Type 2 Diabetes	510	Aug 2024
NCT03087032	LiraGooDLiraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)	P4	Type 2 Diabetes Patients	164	Jan 2019

Liraglutide clinical trials by indication

Diabetes (110)

NCT	Acronym	Phase	Status	Title
NCT05162183	—	N/A	completed	Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data
NCT03936049	—	N/A	completed	Replication of the LEADER Diabetes Trial in Healthcare Claims
NCT01541215	Ellipse™	P3	completed	Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes
NCT03070704	—	N/A	withdrawn	Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India
NCT02730377	LIRA-PRIME	P4	completed	Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
NCT03172494	DUAL™ I China	P3	completed	A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
NCT03175120	DUAL™ II China	P3	completed	A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)
NCT02443155	—	P2	completed	A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function
+ 102 more, see All trials below.

Obesity (44)

NCT	Acronym	Phase	Status	Title
NCT02944500	—	P4	active not recruiting	Saxenda: Underlying Mechanisms and Clinical Outcomes
NCT04775082	SCALE KIDS	P3	active not recruiting	SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
NCT07225816	—	P1	recruiting	Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
NCT05756764	—	N/A	active not recruiting	Anti-obesity Pharmacotherapy and Inflammation
NCT05705388	—	N/A	unknown	POSE2.0 With GLP-1 Agonist for Obesity Management
NCT07374445	—	P4	completed	Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery
NCT06438146	LIROH	P4	unknown	LIROH - Liraglutide for Obesity in HIV
NCT06283641	—	N/A	completed	Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.
+ 36 more, see All trials below.

Type 2 Diabetes (36)

NCT	Acronym	Phase	Status	Title
NCT06559722	—	P3	not yet recruiting	A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
NCT06439056	—	P1	completed	Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D
NCT02344186	—	P4	unknown	Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes
NCT04531176	EMPOWER-T2D	P4	terminated	EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial
NCT04881110	STARDUST	P4	completed	Liraglutide and Peripheral Artery Disease
NCT04057261	Lirabolic	P3	withdrawn	Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease
NCT02960659	—	P1/P2	completed	Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes
NCT04146155	—	P4	unknown	Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease
+ 28 more, see All trials below.

Type 2 Diabetes Mellitus (26)

NCT	Acronym	Phase	Status	Title
NCT05313529	LIGHT-MCI	N/A	active not recruiting	LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
NCT05073692	ON TARGET DM	N/A	completed	Comparison of Type 2 Diabetes Pharmacotherapy Regimens
NCT04535960	NATRIURETIC	P2	unknown	Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial
NCT06099067	HARRP	N/A	completed	Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)
NCT05360147	—	P3	completed	Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus
NCT03555994	—	P2	completed	A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
NCT03707171	—	P3	completed	Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus
NCT02324842	—	N/A	completed	Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients
+ 18 more, see All trials below.

Diabetes Mellitus, Type 2 (21)

NCT	Acronym	Phase	Status	Title
NCT04952779	—	N/A	completed	Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
NCT04529278	LIRADIAL	P2	unknown	Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients
NCT04666987	—	N/A	completed	A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy
NCT04657939	Lean-DM	P4	completed	Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes
NCT03993132	GLP1-RA	N/A	completed	A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
NCT05360537	—	P4	completed	Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients
NCT03823339	INTENSIFY	N/A	completed	A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates
NCT03888157	VIEW-Iran	N/A	completed	A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine
+ 13 more, see All trials below.

Metabolism and Nutrition Disorder (18)

NCT	Acronym	Phase	Status	Title
NCT02527200	—	P3	completed	Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome
NCT02918279	—	P3	completed	Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity
NCT02967757	—	N/A	completed	In-market Utilisation of Liraglutide Used for Weight Management in Europe
NCT02963922	SCALE™ Insulin	P3	completed	Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
NCT02963935	SCALE™ IBT	P3	completed	Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting
NCT02870231	—	P1	completed	Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity
NCT02696148	—	P1	completed	A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years
NCT02453711	—	P2	completed	Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
+ 10 more, see All trials below.

Type 1 Diabetes (15)

NCT	Acronym	Phase	Status	Title
NCT06976619	—	P2	recruiting	The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
NCT05390307	OTID	N/A	completed	Obesity Treatment to Improve Diabetes
NCT02516657	—	P3	completed	Liraglutide in Adolescents With Type 1 Diabetes
NCT02908087	—	P2	completed	Incretin-based Therapy in Early Diagnosed Type 1 Diabetes
NCT02617654	—	P2	completed	Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes
NCT01722240	1966	P3	completed	Liraglutide in Type 1 Diabetes
NCT01722227	—	P3	withdrawn	Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes
NCT01753362	—	P3	completed	Liraglutide In Overweight Patients With Type 1 Diabetes
+ 7 more, see All trials below.

Diabetes Mellitus Type 2 (7)

NCT	Acronym	Phase	Status	Title
NCT02879409	—	N/A	active not recruiting	HbA1c Variability in Type II Diabetes
NCT02655770	—	P4	completed	Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients
NCT02660047	MAGNA VICTORIA	P4	completed	Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent
NCT01761318	MAGNA VICTORIA	P4	completed	Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients
NCT02501850	EGLIPA	P4	unknown	The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)
NCT01542242	—	P4	terminated	Liraglutide Use in Prader-Willi Syndrome
NCT01516476	—	P2	terminated	Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Healthy (6)

NCT	Acronym	Phase	Status	Title
NCT05681299	—	P4	recruiting	Effects of GH and Lirglutide on AgRP
NCT06818292	GLPsy	N/A	completed	Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists
NCT06449703	—	P1	unknown	A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects
NCT05444569	—	P1	completed	A Study of LY3537021 in Healthy Participants
NCT02089256	—	P4	completed	Effect of Repeated Administration of Liraglutide on Insulinogenic Indices
NCT01550653	—	P1	completed	Liraglutide Effects on Memory in Healthy Subjects

Type 1 Diabetes Mellitus (6)

NCT	Acronym	Phase	Status	Title
NCT03632759	—	Early P1	completed	Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D
NCT03011008	—	P4	unknown	Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus
NCT02408705	—	P2	completed	Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects
NCT02518945	—	P3	completed	Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
NCT02109315	DIAB-01	P1	withdrawn	Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.
NCT01299012	—	N/A	completed	Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus

PCOS (5)

NCT	Acronym	Phase	Status	Title
NCT06742710	LITOP	P4	recruiting	Liraglutide Treatment in Obese Infertile PCOS Women
NCT03642600	—	P4	completed	The Gut Microbiome in Women With Polycystic Ovary Syndrome
NCT02187250	—	P4	completed	PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome
NCT01911468	—	P4	completed	Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin
NCT01899430	—	P4	completed	Polycystic Ovary Syndrome and Liraglutide

Diabetes Mellitus, Type 1 (5)

NCT	Acronym	Phase	Status	Title
NCT03182426	T1DM	P1/P2	completed	Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)
NCT05467514	—	P3	completed	Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus
NCT01879917	NewLira	P2/P3	completed	Liraglutide in Newly Onset Type 1 Diabetes.
NCT02138045	TODINELI	N/A	completed	Treatment of Diabetic Neuropathy With Liraglutide
NCT01612468	—	P4	completed	Liraglutide in Type 1 Diabetes

Osteoarthritis (4)

NCT	Acronym	Phase	Status	Title
NCT02905864	LOSEIT	P4	completed	Liraglutide 3 mg for Knee Osteoarthritis
NCT02928614	BIO-LOSEIT-II	P4	completed	Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance
NCT02931383	US-LOSEIT-II	P4	completed	Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance
NCT02928679	IM-LOSEIT-II	P4	completed	Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance

Polycystic Ovary Syndrome (3)

NCT	Acronym	Phase	Status	Title
NCT05952882	—	P3	unknown	Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility
NCT02073929	LIPT	P4	completed	LIPT - Liraglutide in Polycystic Ovary Syndrome
NCT02909933	—	P4	completed	Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity

Diabetes Mellitus (3)

NCT	Acronym	Phase	Status	Title
NCT02231658	—	P1	terminated	Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion
NCT01982630	MK-8521-003	P1	completed	Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)
NCT00993720	—	P2/P3	completed	Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes

Non-alcoholic Fatty Liver Disease (2)

NCT	Acronym	Phase	Status	Title
NCT06501326	—	P4	unknown	Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
NCT02147925	LIGHT-ON	P4	completed	Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects

Weight Loss (2)

NCT	Acronym	Phase	Status	Title
NCT06201819	—	P4	completed	Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery
NCT04325581	—	P3	completed	Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients

Atrial Fibrillation (2)

NCT	Acronym	Phase	Status	Title
NCT03856632	LEAF	P4	active not recruiting	Liraglutide Effect in Atrial Fibrillation
NCT05221229	GOAL-AF	N/A	active not recruiting	Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )

Morbid Obesity (2)

NCT	Acronym	Phase	Status	Title
NCT05285397	—	N/A	unknown	Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.
NCT02616003	—	P4	completed	Preoperative Condition in Giant Obese Patients

Overweight (2)

NCT	Acronym	Phase	Status	Title
NCT04074161	STEP 8	P3	completed	Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
NCT03856047	—	P2	completed	Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Type2 Diabetes (2)

NCT	Acronym	Phase	Status	Title
NCT03883412	ZQL007	P4	unknown	Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)
NCT03260881	—	P4	completed	Liraglutide Effects on Epicardial Fat Inflammatory Genes

Bipolar Disorder (2)

NCT	Acronym	Phase	Status	Title
NCT03158805	—	P2	completed	Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)
NCT02423824	COGDYS-GLP1	P3	completed	Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists

Diabetic Kidney Disease (2)

NCT	Acronym	Phase	Status	Title
NCT02545738	LIRALBU	P4	completed	Antiproteinuric Effects of Liraglutide Treatment
NCT01847313	GLP-1	P3	completed	The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease

Insulin Resistance (2)

NCT	Acronym	Phase	Status	Title
NCT02403284	—	P4	completed	The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans
NCT02140983	LGT	P1	completed	Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes

Gestational Diabetes Mellitus (2)

NCT	Acronym	Phase	Status	Title
NCT01795248	—	P4	completed	The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes
NCT01234649	GDM	P3	completed	Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

Overweight and Obese Adults (1)

NCT	Acronym	Phase	Status	Title
NCT07301437	—	P4	not yet recruiting	RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.

Childhood Obesity (1)

NCT	Acronym	Phase	Status	Title
NCT06836284	—	N/A	recruiting	The Evira Study: Additional Support During Obesity Treatment

Maturity Onset Diabetes of the Young (1)

NCT	Acronym	Phase	Status	Title
NCT07029009	MODY	P2	recruiting	Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)

Obesity, Adolescent (1)

NCT	Acronym	Phase	Status	Title
NCT06865365	—	P4	not yet recruiting	Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone

T2DM (Type 2 Diabetes Mellitus) (1)

NCT	Acronym	Phase	Status	Title
NCT07244003	MESSAGE	P4	recruiting	Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

Delirium, Postoperative (1)

NCT	Acronym	Phase	Status	Title
NCT06361238	—	P3	recruiting	Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery

Polycystic Ovary (1)

NCT	Acronym	Phase	Status	Title
NCT05965908	—	P3	completed	Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome

Multiple Sclerosis (1)

NCT	Acronym	Phase	Status	Title
NCT06171152	—	Early P1	suspended	Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

Diabete Type 2 (1)

NCT	Acronym	Phase	Status	Title
NCT05268237	—	P1/P2	recruiting	Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus

Metformin (1)

NCT	Acronym	Phase	Status	Title
NCT05779644	—	N/A	unknown	Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 Treated With Insulin (1)

NCT	Acronym	Phase	Status	Title
NCT05767255	—	P3	unknown	Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue

Pouchitis (1)

NCT	Acronym	Phase	Status	Title
NCT04763564	—	P2	terminated	Efficacy of Liraglutide Therapy in Patients With IPAA

Opiate Substitution Treatment (1)

NCT	Acronym	Phase	Status	Title
NCT04199728	—	P1/P2	completed	Use of a GLP-1R Agonist to Treat Opioid Use Disorder

Therapeutic Equivalency (1)

NCT	Acronym	Phase	Status	Title
NCT05225974	—	P1	completed	A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects

Mental Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT04781998	—	P4	completed	Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?

Atypical Endometrial Hyperplasia (1)

NCT	Acronym	Phase	Status	Title
NCT04683237	—	P2/P3	withdrawn	Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia

Metabolic Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT04575844	ZQL008	P4	recruiting	Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome

Monoclonal Gammopathies (1)

NCT	Acronym	Phase	Status	Title
NCT02920190	—	P4	withdrawn	Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat

Obese (1)

NCT	Acronym	Phase	Status	Title
NCT04605861	—	P3	completed	The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients

Gestational Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT04324229	Liragest	N/A	active not recruiting	Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes

Type 2 Diabetes Treated With Insulin (1)

NCT	Acronym	Phase	Status	Title
NCT04829903	—	N/A	completed	Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin

Sleep Apnea, Obstructive (1)

NCT	Acronym	Phase	Status	Title
NCT04186494	—	N/A	completed	Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea

Diabetic Neuropathic Pain (1)

NCT	Acronym	Phase	Status	Title
NCT04137328	—	N/A	unknown	Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide

Ischemic Stroke (1)

NCT	Acronym	Phase	Status	Title
NCT03948347	LAMP	N/A	unknown	Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus

Bile Acid Malabsorption (1)

NCT	Acronym	Phase	Status	Title
NCT03955575	BAM-LIRA	P4	completed	Treatment of Bile Acid Malabsorption With Liraglutide

Type 2 Diabetes Patients (1)

NCT	Acronym	Phase	Status	Title
NCT03087032	LiraGooD	P4	recruiting	Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)

Smoking Cessation (1)

NCT	Acronym	Phase	Status	Title
NCT03712098	DAL	P2	completed	Daily Liraglutide for Nicotine Dependence

Pre Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT03480022	SAXAPCOS	P3	completed	Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS

Brain Death (1)

NCT	Acronym	Phase	Status	Title
NCT03672812	—	P3	completed	The Use of Liraglutide in Brain Death

Obesity, Childhood (1)

NCT	Acronym	Phase	Status	Title
NCT03500484	—	Early P1	terminated	Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.

Pulmonary Disease, Chronic Obstructive (1)

NCT	Acronym	Phase	Status	Title
NCT03466021	—	P4	completed	Effects of Liraglutide in Chronic Obstructive Pulmonary Disease

Short Bowel Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT03371862	SLIPS	P2	withdrawn	Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)

Binge-Eating Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT03279731	BELIEVE	P3	terminated	Binge Eating Liraglutide Intervention

Parkinson Disease (1)

NCT	Acronym	Phase	Status	Title
NCT02953665	—	P2	completed	Safety and Efficacy of Liraglutide in Parkinson's Disease

Type1 Diabetes Mellitus (1)

NCT	Acronym	Phase	Status	Title
NCT03011021	—	P1/P2	unknown	Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes

Obesity, Visceral (1)

NCT	Acronym	Phase	Status	Title
NCT03038620	—	P4	completed	Impact of Liraglutide 3.0 on Body Fat Distribution

Osteoarthritis, Knee (1)

NCT	Acronym	Phase	Status	Title
NCT02910570	—	P4	completed	Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis

HIV Infection (1)

NCT	Acronym	Phase	Status	Title
NCT02743598	—	P4	terminated	Liraglutide for HIV-associated Neurocognitive Disorder

Ischemic Cardiomyopathy (1)

NCT	Acronym	Phase	Status	Title
NCT02930265	—	N/A	unknown	Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

GLP-1；Metformin；Telomere-telomerase System；Par-4 (1)

NCT	Acronym	Phase	Status	Title
NCT02535299	Par-4；GLP-1	P4	unknown	Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment

Pre-Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT02488057	—	P4	completed	Improving Beta Cell Function in Mexican American Women With Prediabetes

Autonomic Nervous System Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT03426085	—	P2	unknown	The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes

Microvascular Angina (1)

NCT	Acronym	Phase	Status	Title
NCT02602600	GAP	P4	completed	Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis

Hypoglycemia (1)

NCT	Acronym	Phase	Status	Title
NCT02527993	—	P4	completed	Treatment of Hypoglycemia Following Gastric Bypass Surgery

Diabetes Complications (1)

NCT	Acronym	Phase	Status	Title
NCT02473809	LIRABONE	P4	completed	The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function

Acute ST-segment Elevation Myocardial Infarction (1)

NCT	Acronym	Phase	Status	Title
NCT02507128	—	N/A	unknown	Effects of Glucagon Like Peptide-1 on No-reflow

Heart Failure (1)

NCT	Acronym	Phase	Status	Title
NCT02490176	—	N/A	unknown	Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters

Type II Diabetes Mellitus (1)

NCT	Acronym	Phase	Status	Title
NCT02492763	MK-8521-004	P2	terminated	A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Psoriatic Arthritis (1)

NCT	Acronym	Phase	Status	Title
NCT02472717	PLAQUE	P2	withdrawn	Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study

Hypogonadism (1)

NCT	Acronym	Phase	Status	Title
NCT03619330	—	P4	completed	Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism.

Kidney Failure, Chronic (1)

NCT	Acronym	Phase	Status	Title
NCT02284230	LiRA2	P2	withdrawn	The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure

Diabetes Mellitus, Non-Insulin-Dependent (1)

NCT	Acronym	Phase	Status	Title
NCT02299388	—	P4	completed	To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study

Non-Alcoholic Fatty Liver Disease (1)

NCT	Acronym	Phase	Status	Title
NCT03068065	—	P4	completed	Antidiabetic Effects on Intrahepatic Fat

Cushing's Disease (1)

NCT	Acronym	Phase	Status	Title
NCT02060383	—	P4	completed	Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

Non-alcoholic Fatty Liver Disease (NAFLD) (1)

NCT	Acronym	Phase	Status	Title
NCT02654665	CGH-LiNASH	P3	unknown	Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults

Diabetes Mellitus Type II (1)

NCT	Acronym	Phase	Status	Title
NCT02036372	PILGRIM	N/A	completed	Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus

Glucocorticoid Induced Hyperglycemia (1)

NCT	Acronym	Phase	Status	Title
NCT02016846	—	P3	unknown	Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes

Alzheimer's Disease (1)

NCT	Acronym	Phase	Status	Title
NCT01843075	ELAD	P2	unknown	Evaluating Liraglutide in Alzheimer's Disease

Ischaemic Heart Disease (1)

NCT	Acronym	Phase	Status	Title
NCT02315001	LIONESS	P2	completed	Liraglutide to Improve corONary Haemodynamics During Exercise streSS

Acute Myocardial Infarction (1)

NCT	Acronym	Phase	Status	Title
NCT02001363	—	N/A	unknown	Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

Sleep Apnea (1)

NCT	Acronym	Phase	Status	Title
NCT01832532	SDB	P1/P2	completed	A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks

Impaired Glucose Tolerance Associated With Drugs (1)

NCT	Acronym	Phase	Status	Title
NCT01845259	GREAT	P2	unknown	Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?

Acute Heart Failure (1)

NCT	Acronym	Phase	Status	Title
NCT01800968	FIGHT	P2	completed	Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)

Prediabetes (1)

NCT	Acronym	Phase	Status	Title
NCT01779362	RISE Adult	P3	completed	RISE Adult Medication Study

DIABETES Mellitus Type 2 Not Well Controlled (1)

NCT	Acronym	Phase	Status	Title
NCT01785043	LAED001	P4	completed	Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users

Binge Eating Behaviour (1)

NCT	Acronym	Phase	Status	Title
NCT01739049	—	P4	completed	Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese

Maturity-onset Diabetes of the Young (1)

NCT	Acronym	Phase	Status	Title
NCT01610934	MODY	P2/P3	completed	The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)

Uncontrolled Type 1 Diabetic Patients (1)

NCT	Acronym	Phase	Status	Title
NCT01592279	—	P4	unknown	GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients

Coronary Artery Disease (1)

NCT	Acronym	Phase	Status	Title
NCT01595789	AddHope2	P4	completed	The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes

Alzheimers Disease (1)

NCT	Acronym	Phase	Status	Title
NCT01469351	—	N/A	completed	Identifying Potential Effects of Liraglutide on Degenerative Changes

Congestive Heart Failure (1)

NCT	Acronym	Phase	Status	Title
NCT01425580	—	P2	completed	Liraglutide and Heart Failure in Type 2 Diabetes

Diabetes Mellitus, Type II (1)

NCT	Acronym	Phase	Status	Title
NCT01654120	—	P4	completed	Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics

Hyperglycemia (1)

NCT	Acronym	Phase	Status	Title
NCT01472640	—	N/A	completed	The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus

Psoriasis (1)

NCT	Acronym	Phase	Status	Title
NCT01460069	GLP	N/A	completed	The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis

Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI (1)

NCT	Acronym	Phase	Status	Title
NCT01451905	—	N/A	unknown	GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis

Nonalcoholic Fatty Liver Disease (1)

NCT	Acronym	Phase	Status	Title
NCT01399645	LIRAINS	P2	completed	Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes

Healthy Human Male Subjects (1)

NCT	Acronym	Phase	Status	Title
NCT01695109	—	P4	completed	The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy Volunteers

Nonalcoholic Steatohepatitis (1)

NCT	Acronym	Phase	Status	Title
NCT01237119	LEAN	P2	completed	Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis

Pre-diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT01784965	—	P3	completed	Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.

Liraglutide pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
LITOP	NCT06742710	P4	recruiting	PCOS	890	—
MESSAGE	NCT07244003	P4	recruiting	T2DM (Type 2 Diabetes Mellitus)	430	—
ZQL008	NCT04575844	P4	recruiting	Metabolic Syndrome	80	PMID 16489128
LEAF	NCT03856632	P4	active not recruiting	Atrial Fibrillation	60	—
ZQL007	NCT03883412	P4	unknown	Type2 Diabetes	60	PMID 11078458
LIROH	NCT06438146	P4	unknown	Obesity	40	PMID 33567185
LiraGooD	NCT03087032	P4	recruiting	Type 2 Diabetes Patients	164	—
EMPOWER-T2D	NCT04531176	P4	terminated	Type 2 Diabetes	74	—
STARDUST	NCT04881110	P4	completed	Type 2 Diabetes	60	PMID 36812501
Lean-DM	NCT04657939	P4	completed	Diabetes Mellitus, Type 2	57	PMID 39084829
BAM-LIRA	NCT03955575	P4	completed	Bile Acid Malabsorption	52	—
S-LITE	NCT04122716	P4	unknown	Obesity	215	PMID 36841762
ANGIOSAFE 1	NCT02686177	P4	completed	Type 2 Diabetes	50	PMID 31589290
LIRHV	NCT04008290	P4	unknown	Obesity	15	—
BARIOPTIMISE	NCT03341429	P4	completed	Obesity	70	PMID 37494014
LIRAOB	NCT03347890	P4	completed	Obesity	70	—
Par-4；GLP-1	NCT02535299	P4	unknown	GLP-1；Metformin；Telomere-telomerase System；Par-4	200	—
LIRAFLAME	NCT03449654	P4	completed	Diabetes Mellitus, Type 2	102	PMID 34518158
LIRA-PRIME	NCT02730377	P4	completed	Diabetes	1,991	PMID 30828917
LOSEIT	NCT02905864	P4	completed	Osteoarthritis	150	PMID 39877802
BIO-LOSEIT-II	NCT02928614	P4	completed	Osteoarthritis	150	—
US-LOSEIT-II	NCT02931383	P4	completed	Osteoarthritis	150	—
IM-LOSEIT-II	NCT02928679	P4	completed	Osteoarthritis	150	—
MODEL	NCT02911818	P4	completed	Obesity	150	PMID 30421856
MAGNA VICTORIA	NCT02660047	P4	completed	Diabetes Mellitus Type 2	51	PMID 31288820
SIMPLE	NCT01966978	P4	completed	Diabetes Mellitus, Type 2	157	PMID 31803482
LIRABONE	NCT02473809	P4	completed	Diabetes Complications	60	PMID 18039776
LIGHT-ON	NCT02147925	P4	completed	Non-alcoholic Fatty Liver Disease	75	—
GAP	NCT02602600	P4	completed	Microvascular Angina	33	PMID 23868944
LIRAVIS	NCT02832999	P4	completed	Type 2 Diabetes Mellitus	14	—
GLP1 et Goût	NCT02674893	P4	terminated	Type 2 Diabetes	48	PMID 31405666
LIRALBU	NCT02545738	P4	completed	Diabetic Kidney Disease	32	PMID 37752566
MAGNA VICTORIA	NCT01761318	P4	completed	Diabetes Mellitus Type 2	50	PMID 32127340
LIPT	NCT02073929	P4	completed	Polycystic Ovary Syndrome	72	—
EGLIPA	NCT02501850	P4	unknown	Diabetes Mellitus Type 2	40	PMID 15793200
IMPERIUM	NCT02072096	P4	terminated	Diabetes Mellitus, Type 2	192	PMID 28671753
SAFEGUARD	NCT01744236	P4	completed	Type 2 Diabetes	70	PMID 27038451
AddHope2	NCT01595789	P4	completed	Coronary Artery Disease	41	PMID 33413428
LIRA-SWITCH™	NCT01907854	P4	completed	Diabetes	407	PMID 27381275
LIDO	NCT01787916	P4	completed	Type 1 Diabetes	15	PMID 28722271
ADELANTE	NCT01593137	P4	withdrawn	Type 2 Diabetes	0	—
LIRA-LIXI™	NCT01973231	P4	completed	Diabetes	404	PMID 27311491
LAED001	NCT01785043	P4	completed	DIABETES Mellitus Type 2 Not Well Controlled	13	—
LIRA-Ramadan™	NCT01917656	P4	completed	Diabetes	343	PMID 27376711
Liratime	NCT01499108	P4	completed	Type 2 Diabetes	32	PMID 25935863
BOLT	NCT01755572	P4	completed	Type 2 Diabetes	22	PMID 25414155
EAGLE	NCT01117350	P4	completed	Diabetes Mellitus, Type 2	978	—
T4R	NCT02292290	P4	completed	Type 2 Diabetes	99	—
PREFER	NCT01518101	P4	completed	Type 2 Diabetes	62	PMID 26301063
LIRA-NAFLD/LIP	NCT02721888	P4	terminated	Type 2 Diabetes	127	PMID 30026275
SCALE KIDS	NCT04775082	P3	active not recruiting	Obesity	78	PMID 39258838
Lirabolic	NCT04057261	P3	withdrawn	Type 2 Diabetes	0	—
SAXAPCOS	NCT03480022	P3	completed	Pre Diabetes	88	PMID 35710599
STEP 8	NCT04074161	P3	completed	Overweight	338	PMID 34775881
GRADE	NCT01794143	P3	completed	Type 2 Diabetes	7,850	PMID 31391203
Ellipse™	NCT01541215	P3	completed	Diabetes	135	PMID 33634589
BELIEVE	NCT03279731	P3	terminated	Binge-Eating Disorder	36	—
RISE Adult	NCT01779362	P3	completed	Prediabetes	267	PMID 34274407
1966	NCT01722240	P3	completed	Type 1 Diabetes	69	—
DUAL™ I China	NCT03172494	P3	completed	Diabetes	720	PMID 35762390
GDM	NCT01234649	P3	completed	Gestational Diabetes Mellitus	153	PMID 32046931
DUAL™ II China	NCT03175120	P3	completed	Diabetes	453	—
CGH-LiNASH	NCT02654665	P3	unknown	Non-alcoholic Fatty Liver Disease (NAFLD)	36	PMID 30721572
LixiLan-G	NCT02787551	P3	completed	Type 2 Diabetes Mellitus	514	PMID 35332216
DUAL™ VIII	NCT02501161	P3	completed	Diabetes	1,012	PMID 31189519
SCALE™ Insulin	NCT02963922	P3	completed	Metabolism and Nutrition Disorder	396	PMID 32139381
PIONEER 9	NCT03018028	P3	completed	Diabetes	243	PMID 32333875
SUSTAIN 10	NCT03191396	P3	completed	Diabetes	577	PMID 31539622
SCALE™ IBT	NCT02963935	P3	completed	Metabolism and Nutrition Disorder	282	PMID 32090517
PIONEER 4	NCT02863419	P3	completed	Diabetes	711	PMID 31186120
DUAL™ I Japan	NCT02607306	P3	completed	Diabetes	819	PMID 33595901
DUAL™ II Japan	NCT02911948	P3	completed	Diabetes	210	PMID 31423685
DUALTM IX	NCT02773368	P3	completed	Diabetes	420	PMID 30761720
LYDIA	NCT02043054	P3	completed	Type 2 Diabetes Mellitus	90	PMID 27440110
i-LAB	NCT02718950	P3	unknown	Obesity	20	—
COGDYS-GLP1	NCT02423824	P3	completed	Bipolar Disorder	21	—
DUAL™ VI	NCT02298192	P3	completed	Diabetes	420	PMID 28124817
LEADER®	NCT01179048	P3	completed	Diabetes	9,341	PMID 30392095
GLP-1	NCT01847313	P3	completed	Diabetic Kidney Disease	20	PMID 16177002
SAIL	NCT01628445	P3	terminated	Type 2 Diabetes	52	—
ADJUNCT ONE™	NCT01836523	P3	completed	Diabetes	1,398	PMID 27506222
ADJUNCT TWO™	NCT02098395	P3	completed	Diabetes	835	PMID 27493232
DUAL™	NCT02100475	P3	completed	Diabetes	31	—
T2DM	NCT01733758	P3	completed	Diabetes Mellitus, Type 2	494	—
DUAL™ V	NCT01952145	P3	completed	Diabetes	557	PMID 29276398
T1DMLIRA	NCT02092896	P3	completed	Diabetes	40	PMID 26486191
LIBRA	NCT01270789	P3	completed	Type 2 Diabetes	63	PMID 25495067
DUAL™ III	NCT01676116	P3	completed	Diabetes	438	PMID 27943107
AWARD-6	NCT01624259	P3	completed	Type 2 Diabetes	599	PMID 26691396
DUAL™IV	NCT01618162	P3	completed	Diabetes	435	PMID 27589252
DUAL™ I	NCT01336023	P3	completed	Diabetes	1,663	PMID 26894800
DUAL™ II	NCT01392573	P3	completed	Diabetes	413	PMID 28282219
BEGIN™	NCT01388361	P3	completed	Diabetes	413	PMID 24443830
MK-0431-403	NCT01296412	P3	completed	Diabetes Mellitus, Type 2	653	PMID 23604551
LEAD-6	NCT00518882	P3	completed	Diabetes	467	PMID 22018679
LEAD-2	NCT00318461	P3	completed	Diabetes	1,091	PMID 21883806
LEAD-3	NCT00294723	P3	terminated	Diabetes	746	PMID 22174428
SU	NCT00395746	P3	completed	Diabetes	264	PMID 20380655
LEAD-4	NCT00333151	P3	completed	Diabetes	576	PMID 19289857
LEAD-1	NCT00318422	P3	completed	Diabetes	1,041	PMID 19317822
LEAD-5	NCT00331851	P3	completed	Diabetes	584	PMID 19245711
MODY	NCT07029009	P2	recruiting	Maturity Onset Diabetes of the Young	50	—
R	NCT04883346	P2	completed	Obesity	34	PMID 26544725
LIRADIAL	NCT04529278	P2	unknown	Diabetes Mellitus, Type 2	18	PMID 22383694
NATRIURETIC	NCT04535960	P2	unknown	Type 2 Diabetes Mellitus	36	—
DAL	NCT03712098	P2	completed	Smoking Cessation	40	—
SLIPS	NCT03371862	P2	withdrawn	Short Bowel Syndrome	0	—
ELAD	NCT01843075	P2	unknown	Alzheimer's Disease	204	PMID 30944040
MK-8521-004	NCT02492763	P2	terminated	Type II Diabetes Mellitus	176	—
GREAT	NCT01845259	P2	unknown	Impaired Glucose Tolerance Associated With Drugs	103	PMID 25023888
PLAQUE	NCT02472717	P2	withdrawn	Psoriatic Arthritis	0	—
FIGHT	NCT01800968	P2	completed	Acute Heart Failure	300	PMID 30120812
LiRA2	NCT02284230	P2	withdrawn	Kidney Failure, Chronic	0	—
LIONESS	NCT02315001	P2	completed	Ischaemic Heart Disease	26	PMID 33579317
LEAN	NCT01237119	P2	completed	Nonalcoholic Steatohepatitis	52	PMID 26394161
LIRAINS	NCT01399645	P2	completed	Nonalcoholic Fatty Liver Disease	35	PMID 25813773

Terminated and withdrawn Liraglutide trials (33)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT06171152suspendedStudy of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
NCT04683237withdrawnLiraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia
NCT04763564terminatedEfficacy of Liraglutide Therapy in Patients With IPAA
NCT04531176terminatedEMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial
NCT04057261withdrawnEffect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease
NCT05438186withdrawnINSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records
NCT04643301withdrawnLiraglutide for Low-responders After Bariatric Surgery
NCT02920190withdrawnAntigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat
NCT04839237withdrawnThe Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients
NCT02198209withdrawnLiraglutide Actions on the Liver: Effects on Glucose Phosphorylation
NCT03371862withdrawnLiraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)
NCT03500484terminatedEffect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.
NCT03279731terminatedBinge Eating Liraglutide Intervention
NCT03070704withdrawnNon-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India
NCT02743598terminatedLiraglutide for HIV-associated Neurocognitive Disorder
NCT02231658terminatedEffects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion
NCT01722227withdrawnAnti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes
NCT02492763terminatedA Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)
NCT02417103terminatedPretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid
NCT02472717withdrawnPsoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study
NCT02674893terminatedEffect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes
NCT01628445terminatedStudy of Liraglutide in Individuals With Type 2 Diabetes Using Insulin
NCT02072096terminatedA Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
NCT02284230withdrawnThe Effect of Liraglutide in Patients With Prediabetes and Kidney Failure
NCT02109315withdrawnVitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.
NCT01593137withdrawnA Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes
NCT01597531terminatedCombinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding
NCT01638260terminatedGLP-1 and Non-exercise Activity Thermogenesis in RHZ
NCT01206101terminatedEfficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
NCT01542242terminatedLiraglutide Use in Prader-Willi Syndrome
NCT02721888terminatedEffect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism
NCT01516476terminatedStudy of RO6807952 in Patients With Diabetes Mellitus Type 2
NCT00294723terminatedTo Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c

All Liraglutide trials (408)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT06742710	LITOP	Liraglutide Treatment in Obese Infertile PCOS Women	P4	recruiting	890	Peking University Third Hospital	May 2025
NCT06976619		The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes	P2	recruiting	60	Mayo Clinic	Oct 2025
NCT07244003	MESSAGE	Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control	P4	recruiting	430	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Mar 2025
NCT05681299		Effects of GH and Lirglutide on AgRP	P4	recruiting	40	Columbia University	May 2023
NCT06361238		Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery	P3	recruiting	260	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Nov 2024
NCT06865365		Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone	P4	not yet recruiting	72	Medical University of Vienna	May 2025
NCT04324229	Liragest	Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes	N/A	active not recruiting	80	Turku University Hospital	Feb 2020
NCT06171152		Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues	Early P1	suspended	30	University of Chicago	Jan 2024
NCT07301437		RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.	P4	not yet recruiting	120	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	May 2026
NCT02944500		Saxenda: Underlying Mechanisms and Clinical Outcomes	P4	active not recruiting	28	Beth Israel Deaconess Medical Center	Nov 2016
NCT06836284		The Evira Study: Additional Support During Obesity Treatment	N/A	recruiting	40	Karolinska Institutet	Feb 2026
NCT04575844	ZQL008	Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome	P4	recruiting	80	University of Virginia	Nov 2020
NCT04775082	SCALE KIDS	SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity	P3	active not recruiting	78	Novo Nordisk A/S	Mar 2021
NCT07029009	MODY	Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)	P2	recruiting	50	Mansa	May 2025
NCT03856632	LEAF	Liraglutide Effect in Atrial Fibrillation	P4	active not recruiting	60	University of Miami	Mar 2019
NCT04683237		Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia	P2/P3	withdrawn	0	Xiaojun Chen	Mar 2021
NCT02879409		HbA1c Variability in Type II Diabetes	N/A	active not recruiting	150	Weill Cornell Medical College in Qatar	Nov 2016
NCT05313529	LIGHT-MCI	LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes	N/A	active not recruiting	396	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Oct 2022
NCT07225816		Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)	P1	recruiting	75	Novo Nordisk A/S	Nov 2025
NCT05221229	GOAL-AF	Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )	—	active not recruiting	29	University Hospital Birmingham	Apr 2022
NCT05268237		Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus	P1/P2	recruiting	15	Biolingus	Apr 2023
NCT06559722		A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes	P3	not yet recruiting	510	Tonghua Dongbao Pharmaceutical Co.,Ltd	Aug 2024
NCT05756764		Anti-obesity Pharmacotherapy and Inflammation	—	active not recruiting	30	Louisiana State University Health Sciences Center in New Orleans	Jun 2023
NCT05705388		POSE2.0 With GLP-1 Agonist for Obesity Management	N/A	unknown	50	Emirates Health Services (EHS)	Jan 2023
NCT05952882		Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility	P3	unknown	188	Mỹ Đức Hospital	Nov 2023
NCT03883412	ZQL007	Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)	P4	unknown	60	University of Virginia	Feb 2019
NCT06439056		Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D	P1	completed	12	Nanexa AB	May 2024
NCT03011021		Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes	P1/P2	unknown	40	Second Xiangya Hospital of Central South University	Jan 2017
NCT07374445		Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery	P4	completed	100	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Sep 2023
NCT06438146	LIROH	LIROH - Liraglutide for Obesity in HIV	P4	unknown	40	Brigham and Women's Hospital	May 2024
NCT05965908		Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome	P3	completed	150	Beni-Suef University	Jan 2024
NCT05073692	ON TARGET DM	Comparison of Type 2 Diabetes Pharmacotherapy Regimens	—	completed	241,981	Kaiser Permanente	Jul 2021
NCT06501326		Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease	P4	unknown	102	Affiliated Hospital of Nantong University	Nov 2023
NCT05779644		Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus	N/A	unknown	300	RenJi Hospital	Feb 2023
NCT03087032	LiraGooD	Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)	P4	recruiting	164	The First Affiliated Hospital of Xiamen University	Jan 2019
NCT06283641		Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.	—	completed	300	Novo Nordisk A/S	Apr 2024
NCT04952779		Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea	—	completed	750	Novo Nordisk A/S	Jun 2021
NCT06818292	GLPsy	Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists	N/A	completed	10	Nils Opel	Oct 2024
NCT05579249		A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America	P4	completed	500	Novo Nordisk A/S	Jan 2023
NCT03260881		Liraglutide Effects on Epicardial Fat Inflammatory Genes	P4	completed	38	University of Miami	Sep 2018
NCT03182426	T1DM	Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)	P1/P2	completed	22	University of Alberta	Aug 2017
NCT03948347	LAMP	Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus	N/A	unknown	1,708	First Affiliated Hospital of Jinan University	Jun 2019
NCT06449703		A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects	P1	unknown	44	Tonghua Dongbao Pharmaceutical Co.,Ltd	May 2024
NCT04883346	R	Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy	P2	completed	34	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Jun 2021
NCT05390307	OTID	Obesity Treatment to Improve Diabetes	N/A	completed	60	Dasman Diabetes Institute	Apr 2023
NCT04529278	LIRADIAL	Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients	P2	unknown	18	Fondation Hôpital Saint-Joseph	Jan 2021
NCT02344186		Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	P4	unknown	12	Temple University	May 2014
NCT02403284		The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans	P4	completed	97	Phoenix VA Health Care System	Mar 2013
NCT04535960	NATRIURETIC	Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial	P2	unknown	36	University Health Network, Toronto	Jan 2019
NCT04763564		Efficacy of Liraglutide Therapy in Patients With IPAA	P2	terminated	8	University of North Carolina, Chapel Hill	Mar 2022
NCT04199728		Use of a GLP-1R Agonist to Treat Opioid Use Disorder	P1/P2	completed	27	Milton S. Hershey Medical Center	Oct 2021
NCT06099067	HARRP	Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)	—	completed	239,990	AstraZeneca	May 2020
NCT05767255		Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue	P3	unknown	66	Hospital Universitario San Ignacio	Dec 2022
NCT04531176	EMPOWER-T2D	EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial	P4	terminated	74	The Cleveland Clinic	Sep 2020
NCT02516657		Liraglutide in Adolescents With Type 1 Diabetes	P3	completed	5	University at Buffalo	May 2012
NCT04575194		Study of the Cardiometabolic Effects of Obesity Pharmacotherapy	P4	unknown	40	National and Kapodistrian University of Athens	Sep 2020
NCT06201819		Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery	P4	completed	37	Hospital Civil Juan I. Menchaca	Dec 2022
NCT04605861		The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients	P3	completed	414	Shanghai Zhongshan Hospital	Aug 2020
NCT05467514		Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus	P3	completed	35	David Sanchez Garcia	Jul 2022
NCT05444569		A Study of LY3537021 in Healthy Participants	P1	completed	47	Eli Lilly and Company	Aug 2022
NCT04666987		A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy	—	completed	359	Novo Nordisk A/S	Oct 2020
NCT05268627		Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight Loss	N/A	unknown	38	Mansoura University	Jan 2022
NCT03158805		Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)	P2	completed	60	Lindner Center of HOPE	Apr 2017
NCT04881110	STARDUST	Liraglutide and Peripheral Artery Disease	P4	completed	60	University of Campania Luigi Vanvitelli	Feb 2021
NCT04311411		A Study of Tirzepatide in Overweight and Very Overweight Participants	P1	completed	114	Eli Lilly and Company	Aug 2020
NCT04057261	Lirabolic	Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease	P3	withdrawn	0	RWTH Aachen University	Nov 2020
NCT04137328		Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide	N/A	unknown	60	Fudan University	Nov 2019
NCT05438186	INSPIRE Turkey	INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records	—	withdrawn	0	Novo Nordisk A/S	Sep 2022
NCT04657939	Lean-DM	Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes	P4	completed	57	University of Leeds	Dec 2020
NCT05285397		Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.	N/A	unknown	60	General Committee of Teaching Hospitals and Institutes, Egypt	Mar 2022
NCT03479762		In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database	—	completed	105	Novo Nordisk A/S	Apr 2018
NCT04781998		Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?	P4	completed	24	Anders Fink-Jensen, MD, DMSci	Jul 2021
NCT03671733		Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients	P3	unknown	150	Xiangya Hospital of Central South University	Sep 2018
NCT02953665		Safety and Efficacy of Liraglutide in Parkinson's Disease	P2	completed	63	Cedars-Sinai Medical Center	Apr 2017
NCT04186494		Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea	N/A	completed	30	St Vincent's University Hospital, Ireland	Dec 2019
NCT04525300		Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities	P3	unknown	300	Xiangya Hospital of Central South University	May 2020
NCT04487743		Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities	P3	unknown	300	Xiangya Hospital of Central South University	May 2020
NCT03993132	GLP1-RA	A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes	—	completed	26,774	Boehringer Ingelheim	Oct 2018
NCT03955575	BAM-LIRA	Treatment of Bile Acid Malabsorption With Liraglutide	P4	completed	52	Filip Krag Knop	Mar 2019
NCT03374956		Individualized Obesity Pharmacotherapy	P3	completed	193	Mayo Clinic	Dec 2017
NCT03712098	DAL	Daily Liraglutide for Nicotine Dependence	P2	completed	40	Rebecca Ashare	Nov 2018
NCT02960659		Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes	P1/P2	completed	24	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	May 2017
NCT05360537		Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients	P4	completed	100	University of Palermo	Apr 2021
NCT02773355		Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients	—	completed	27	Novo Nordisk A/S	May 2016
NCT03672812		The Use of Liraglutide in Brain Death	P3	completed	50	Hospital de Clinicas de Porto Alegre	Sep 2018
NCT04643301	LIBAR	Liraglutide for Low-responders After Bariatric Surgery	N/A	withdrawn	0	Zuyderland Medisch Centrum	Dec 2020
NCT02920190		Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat	P4	withdrawn	0	University of Miami	Sep 2020
NCT04146155		Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease	P4	unknown	200	Second Affiliated Hospital, School of Medicine, Zhejiang University	May 2020
NCT03986008		Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients	P3	unknown	60	Xiangya Hospital of Central South University	Dec 2019
NCT04839237		The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients	P2	withdrawn	0	Xiangya Hospital of Central South University	Dec 2017
NCT04122716	S-LITE	Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet	P4	unknown	215	Signe Torekov	Sep 2016
NCT04829903		Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin	N/A	completed	116	Corporacion Parc Tauli	Jan 2020
NCT03632759		Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D	Early P1	completed	16	Carla Greenbaum, MD	Aug 2018
NCT05162183		Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data	—	completed	3,474	Brigham and Women's Hospital	Sep 2019
NCT03523273		Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity	P2	completed	136	Michael Camilleri, MD	Nov 2017
NCT05225974		A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects	P1	completed	32	The Affiliated Hospital of Qingdao University	Jul 2021
NCT03011008		Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus	P4	unknown	20	Second Xiangya Hospital of Central South University	Jan 2017
NCT03101930		Cardiovascular Effects of GLP-1 Receptor Activation	P4	completed	329	Vanderbilt University Medical Center	May 2017
NCT02908087		Incretin-based Therapy in Early Diagnosed Type 1 Diabetes	P2	completed	13	University of Oulu	Mar 2016
NCT02686177	ANGIOSAFE 1	Effect of GLP-1 on Angiogenesis	P4	completed	50	Assistance Publique - Hôpitaux de Paris	May 2016
NCT03480022	SAXAPCOS	Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS	P3	completed	88	Woman's	Sep 2018
NCT04074161	STEP 8	Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity	P3	completed	338	Novo Nordisk A/S	Sep 2019
NCT05360147		Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus	P3	completed	30	Third Military Medical University	Jan 2021
NCT01794143	GRADE	A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes	P3	completed	7,850	GRADE Study Group	May 2013
NCT03555994		A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.	P2	completed	51	MedImmune LLC	May 2018
NCT04008290	LIRHV	The Effect of Liraglutide on the GIT	P4	unknown	15	Universitaire Ziekenhuizen KU Leuven	Apr 2020
NCT03856047		Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.	P2	completed	706	Novo Nordisk A/S	Mar 2019
NCT03936049		Replication of the LEADER Diabetes Trial in Healthcare Claims	—	completed	168,690	Brigham and Women's Hospital	Sep 2017
NCT02198209		Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation	P4	withdrawn	0	Cedars-Sinai Medical Center	Dec 2019
NCT03823339	INTENSIFY	A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates	—	completed	300	Novo Nordisk A/S	Jan 2019
NCT03560336		A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.	—	completed	758	Novo Nordisk A/S	Jul 2018
NCT05294536	RD12014	A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects	P1	completed	50	Sunshine Lake Pharma Co., Ltd.	Jun 2020
NCT02527200		Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome	P3	completed	56	Novo Nordisk A/S	Nov 2015
NCT03888157	VIEW-Iran	A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine	—	completed	839	Novo Nordisk A/S	Mar 2019
NCT03038620		Impact of Liraglutide 3.0 on Body Fat Distribution	P4	completed	235	University of Texas Southwestern Medical Center	Jan 2017
NCT03371862	SLIPS	Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)	P2	withdrawn	0	Imperial College London	Oct 2017
NCT02617654		Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes	P2	completed	18	Per-Ola Carlsson	Nov 2015
NCT01795248		The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes	P4	completed	105	Tina Vilsboll	Jul 2012
NCT03426085		The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes	P2	unknown	44	Eastern Virginia Medical School	May 2016
NCT01919489		Liraglutide Hospital Discharge Trial	P4	completed	273	Emory University	Mar 2014
NCT03642600		The Gut Microbiome in Women With Polycystic Ovary Syndrome	P4	completed	21	Universitaire Ziekenhuizen KU Leuven	Feb 2019
NCT03500484		Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.	Early P1	terminated	13	Yale University	Jun 2018
NCT03341429	BARIOPTIMISE	Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response	P4	completed	70	University College, London	Aug 2018
NCT03466021		Effects of Liraglutide in Chronic Obstructive Pulmonary Disease	P4	completed	40	Claus Bogh Juhl	Jan 2018
NCT01541215	Ellipse™	Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes	P3	completed	135	Novo Nordisk A/S	Nov 2012
NCT04046822		Effect of Liraglutide on Microbiome in Obesity	P4	unknown	70	Federico II University	Jan 2019
NCT03347890	LIRAOB	Reward Mechanisms in Obesity	P4	completed	70	Zoltan Pataky	Mar 2018
NCT03520062	LIRAP	The Effect of Liraglutide on Pancreatic Hormones and Its Size	N/A	completed	14	Nicolai Jacob Wewer Albrechtsen	Aug 2017
NCT02535299	Par-4；GLP-1	Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment	P4	unknown	200	Third Military Medical University	Jun 2016
NCT02655770		Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients	P4	completed	40	Rigshospitalet, Denmark	Feb 2016
NCT01843075	ELAD	Evaluating Liraglutide in Alzheimer's Disease	P2	unknown	204	Imperial College London	Jan 2014
NCT03757130		Multiple Ascending Dose Study of AMG 598 in Adults With Obesity	P1	completed	50	Amgen	Nov 2018
NCT02889510		Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus	P3	completed	76	Lecube, Albert, M.D.	Oct 2016
NCT03421119		Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes	P3	unknown	300	Cinnagen	Jun 2019
NCT03279731	BELIEVE	Binge Eating Liraglutide Intervention	P3	terminated	36	Kelly Allison	Sep 2017
NCT02650206		Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood	P1	completed	56	Stanford University	Jan 2015
NCT01779362	RISE Adult	RISE Adult Medication Study	P3	completed	267	RISE Study Group	Apr 2013
NCT03449654	LIRAFLAME	Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes	P4	completed	102	Steno Diabetes Center Copenhagen	Oct 2017
NCT03070704		Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India	—	withdrawn	0	Novo Nordisk A/S	Aug 2017
NCT02730377	LIRA-PRIME	Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes	P4	completed	1,991	Novo Nordisk A/S	Mar 2016
NCT02918279		Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity	P3	completed	251	Novo Nordisk A/S	Sep 2016
NCT01722240	1966	Liraglutide in Type 1 Diabetes	P3	completed	69	University at Buffalo	Nov 2012
NCT03172494	DUAL™ I China	A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)	P3	completed	720	Novo Nordisk A/S	May 2017
NCT05029076		Human Bioequivalence Test of Liraglutide Injection	P1	completed	28	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	May 2019
NCT03235050		A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes	P2	completed	834	AstraZeneca	Aug 2017
NCT01234649	GDM	Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)	P3	completed	153	Woman's	Aug 2011
NCT02967757		In-market Utilisation of Liraglutide Used for Weight Management in Europe	—	completed	316	Novo Nordisk A/S	Dec 2016
NCT03707171		Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus	P3	completed	30	Third Military Medical University	Oct 2018
NCT02082496		GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations	P2	completed	50	University of Copenhagen	Jun 2014
NCT03175120	DUAL™ II China	A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)	P3	completed	453	Novo Nordisk A/S	May 2017
NCT02905864	LOSEIT	Liraglutide 3 mg for Knee Osteoarthritis	P4	completed	150	Henrik Gudbergsen	Nov 2016
NCT02928614	BIO-LOSEIT-II	Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance	P4	completed	150	Henrik Gudbergsen	Nov 2016
NCT02910570		Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis	P4	completed	150	Parker Research Institute	Nov 2016
NCT02931383	US-LOSEIT-II	Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance	P4	completed	150	Henrik Gudbergsen	Nov 2016
NCT02488057		Improving Beta Cell Function in Mexican American Women With Prediabetes	P4	completed	360	Ohio State University	May 2016
NCT02324842		Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients	N/A	completed	45	The University of Texas Health Science Center at San Antonio	Nov 2014
NCT02928679	IM-LOSEIT-II	Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance	P4	completed	150	Henrik Gudbergsen	Nov 2016
NCT03486392		A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants	P2	completed	474	Janssen Research & Development, LLC	Mar 2018
NCT02765399		The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis	P4	completed	23	Helsinki University Central Hospital	Feb 2015
NCT02443155		A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function	P2	completed	308	Novo Nordisk A/S	Nov 2015
NCT02911818	MODEL	Lifestyle Modification and Liraglutide	P4	completed	150	University of Pennsylvania	Sep 2016
NCT04325581		Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients	P3	completed	16	Post Graduate Institute of Medical Education and Research, Chandigarh	Aug 2016
NCT02654665	CGH-LiNASH	Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults	P3	unknown	36	Changi General Hospital	Mar 2014
NCT02787551	LixiLan-G	Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period	P3	completed	514	Sanofi	Jul 2016
NCT02501161	DUAL™ VIII	A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus	P3	completed	1,012	Novo Nordisk A/S	Jan 2016
NCT02743598		Liraglutide for HIV-associated Neurocognitive Disorder	P4	terminated	4	Temple University	Sep 2016
NCT02963922	SCALE™ Insulin	Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin	P3	completed	396	Novo Nordisk A/S	Feb 2017
NCT01879917	NewLira	Liraglutide in Newly Onset Type 1 Diabetes.	P2/P3	completed	65	Hvidovre University Hospital	Feb 2014
NCT03018028	PIONEER 9	Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes	P3	completed	243	Novo Nordisk A/S	Jan 2017
NCT03191396	SUSTAIN 10	Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes	P3	completed	577	Novo Nordisk A/S	Jun 2017
NCT02231658		Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion	P1	terminated	109	Profil Institut für Stoffwechselforschung GmbH	Jul 2015
NCT02963935	SCALE™ IBT	Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting	P3	completed	282	Novo Nordisk A/S	Feb 2017
NCT01722227		Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes	P3	withdrawn	0	University at Buffalo	Nov 2012
NCT02964247		LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.	P3	completed	303	Novo Nordisk A/S	Mar 2017
NCT02616003		Preoperative Condition in Giant Obese Patients	P4	completed	50	Sana Klinikum Offenbach	Apr 2014
NCT03115099		A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes	P1	completed	80	Eli Lilly and Company	May 2017
NCT02930265		Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy	N/A	unknown	400	Chinese PLA General Hospital	Sep 2016
NCT02863419	PIONEER 4	Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus	P3	completed	711	Novo Nordisk A/S	Aug 2016
NCT02060383		Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly	P4	completed	249	Novartis Pharmaceuticals	May 2014
NCT02660047	MAGNA VICTORIA	Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent	P4	completed	51	Leiden University Medical Center	Aug 2015
NCT01753362		Liraglutide In Overweight Patients With Type 1 Diabetes	P3	completed	84	University at Buffalo	Dec 2012
NCT03041792		Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects	P1	completed	61	Pfizer	Feb 2017
NCT03292185		A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects	P1	completed	24	Novo Nordisk A/S	Sep 2017
NCT03010683	GLP-1R	Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus	N/A	completed	60	University of Athens	Nov 2015
NCT01966978	SIMPLE	The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study	P4	completed	157	University of Texas Southwestern Medical Center	Nov 2014
NCT02973321		A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus	P2	completed	296	Sanofi	Dec 2016
NCT02607306	DUAL™ I Japan	A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.	P3	completed	819	Novo Nordisk A/S	Nov 2015
NCT02911948	DUAL™ II Japan	A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs	P3	completed	210	Novo Nordisk A/S	Sep 2016
NCT02505334		A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.	P3	completed	635	Novo Nordisk A/S	Jul 2015
NCT02638805		Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide	P3	completed	136	Intarcia Therapeutics	Dec 2015
NCT02473809	LIRABONE	The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function	P4	completed	60	University of Aarhus	Aug 2015
NCT02773368	DUALTM IX	A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus	P3	completed	420	Novo Nordisk A/S	May 2016
NCT02043054	LYDIA	Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)	P3	completed	90	University of Leicester	Dec 2013
NCT01232946		Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake	N/A	completed	30	Indiana University	Jan 2012
NCT02870231		Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity	P1	completed	187	Novo Nordisk A/S	Aug 2016
NCT02783196	LIR-CG	Effect of Liraglutide on Clock Genes	N/A	unknown	14	Tel Aviv University	Jul 2016
NCT02321878		Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)	—	completed	1,092	Novo Nordisk A/S	Dec 2014
NCT02718950	i-LAB	Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans	P3	unknown	20	University of Campinas, Brazil	Jun 2016
NCT02147925	LIGHT-ON	Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects	P4	completed	75	Sun Yat-sen University	Aug 2014
NCT02602600	GAP	Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis	P4	completed	33	Eva Prescott	Nov 2015
NCT02492763	MK-8521-004	A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)	P2	terminated	176	Merck Sharp & Dohme LLC	Jul 2015
NCT02696148		A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years	P1	completed	24	Novo Nordisk A/S	Mar 2016
NCT02453711		Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus	P2	completed	957	Novo Nordisk A/S	Oct 2015
NCT03534310	LETHE	Weight Loss With Intensive Lifestyle Modifications Plus Bariatric Surgery Versus Liraglutide 3 mg	N/A	completed	75	Catholic University of the Sacred Heart	Nov 2015
NCT02527993		Treatment of Hypoglycemia Following Gastric Bypass Surgery	P4	completed	11	Zealand University Hospital	Oct 2015
NCT02014740		Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes	P4	completed	100	University of Miami	Mar 2014
NCT02055014		Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)	P4	unknown	72	Sandwell & West Birmingham Hospitals NHS Trust	Jul 2013
NCT01845259	GREAT	Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?	P2	unknown	103	Psychiatric Centre Rigshospitalet	Apr 2013
NCT01821846		Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus	—	completed	64	Novo Nordisk A/S	Nov 2013
NCT02138045	TODINELI	Treatment of Diabetic Neuropathy With Liraglutide	N/A	completed	39	Aalborg University Hospital	May 2014
NCT02140983	LGT	Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes	P1	completed	41	Stanford University	Aug 2013
NCT02717858		A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.	P1	completed	52	Novo Nordisk A/S	Mar 2016
NCT02036372	PILGRIM	Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus	N/A	completed	150	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Jan 2014
NCT02832999	LIRAVIS	Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes	P4	completed	14	Yaounde Central Hospital	Jan 2016
NCT02299388		To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study	P4	completed	11	Tulane University School of Medicine	Oct 2014
NCT03034941		Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients	P4	completed	35	University Medical Centre Ljubljana	Apr 2014
NCT02417103		Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid	P3	terminated	2	Universitätsklinikum Hamburg-Eppendorf	Dec 2011
NCT02647944		Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity	P2	completed	40	Mayo Clinic	Dec 2015
NCT02472717	PLAQUE	Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study	P2	withdrawn	0	University Health Network, Toronto	May 2015
NCT02351232		The Lira Pump Trial	P2/P3	completed	44	Hvidovre University Hospital	Feb 2015
NCT02754817		A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus	—	completed	611	Novo Nordisk A/S	Apr 2016
NCT02461589		Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes	P2	completed	706	Novo Nordisk A/S	Sep 2015
NCT02420262		A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus	P3	completed	506	Novo Nordisk A/S	Jul 2015
NCT02503943		Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes	P4	unknown	90	Third Affiliated Hospital of Third Military Medical University	May 2015
NCT02674893	GLP1 et Goût	Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes	P4	terminated	48	Centre Hospitalier Universitaire Dijon	Feb 2014
NCT01425580		Liraglutide and Heart Failure in Type 2 Diabetes	P2	completed	62	Thomas Nystrom	Jan 2012
NCT02507128		Effects of Glucagon Like Peptide-1 on No-reflow	N/A	unknown	190	Chen Wei Ren, MD	Jul 2015
NCT02490176		Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters	N/A	unknown	50	Chinese PLA General Hospital	Jul 2015
NCT02235961		Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects	P1	completed	163	Novo Nordisk A/S	Sep 2014
NCT01505673		Adding Liraglutide to High Dose Insulin: Breaking the Cycle	P4	completed	71	Ildiko Lingvay	Jan 2012
NCT02423824	COGDYS-GLP1	Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists	P3	completed	21	University Health Network, Toronto	May 2015
NCT02545738	LIRALBU	Antiproteinuric Effects of Liraglutide Treatment	P4	completed	32	Steno Diabetes Center Copenhagen	Apr 2015
NCT02408705		Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects	P2	completed	14	Medical University of Graz	Jan 2015
NCT02518945		Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes	P3	completed	26	University at Buffalo	Aug 2015
NCT01761318	MAGNA VICTORIA	Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients	P4	completed	50	Leiden University Medical Center	Nov 2013
NCT02001363		Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury	N/A	unknown	90	Chen Wei Ren, MD	Nov 2013
NCT01740921	GLP-1ADDS	GLP-1 and Microvascular Function in Type 2 Diabetes	N/A	completed	39	Royal Devon and Exeter NHS Foundation Trust	Jan 2011
NCT02073929	LIPT	LIPT - Liraglutide in Polycystic Ovary Syndrome	P4	completed	72	Jens Faber	Mar 2014
NCT01832532	SDB	A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks	P1/P2	completed	34	Children's Hospital Medical Center, Cincinnati	Apr 2013
NCT01790308		Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function	P4	unknown	100	Sun Yat-sen University	Feb 2013
NCT01403025		Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes	—	completed	4,121	Novo Nordisk A/S	Jul 2011
NCT02298192	DUAL™ VI	A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms	P3	completed	420	Novo Nordisk A/S	Nov 2014
NCT01179048	LEADER®	Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results	P3	completed	9,341	Novo Nordisk A/S	Aug 2010
NCT01575301	DIRECTGLP	DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists	N/A	completed	411	University of Dundee	Mar 2011
NCT01847313	GLP-1	The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease	P3	completed	20	Karl Neff	Apr 2013
NCT01856790		Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes	Early P1	completed	15	Jennifer Sherr	Feb 2013
NCT01628445	SAIL	Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin	P3	terminated	52	University of Manitoba	Aug 2012
NCT02255266		Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice	—	completed	1,788	Novo Nordisk A/S	Mar 2015
NCT02909933		Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity	P4	completed	30	University Medical Centre Ljubljana	Jul 2015
NCT02501850	EGLIPA	The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)	P4	unknown	40	Hospital Universitari Vall d'Hebron Research Institute	Oct 2014
NCT03068065		Antidiabetic Effects on Intrahepatic Fat	P4	completed	87	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	May 2014
NCT02072096	IMPERIUM	A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)	P4	terminated	192	Eli Lilly and Company	Feb 2014
NCT01800968	FIGHT	Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)	P2	completed	300	Duke University	Apr 2013
NCT01472640		The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus	N/A	completed	240	Flyvbjerg, Allan, DMSc	Nov 2011
NCT02205528		A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin	P2	completed	108	Novo Nordisk A/S	Aug 2014
NCT03619330		Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism.	P4	completed	30	University Medical Centre Ljubljana	Dec 2014
NCT02284230	LiRA2	The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure	P2	withdrawn	0	Bo Feldt-Rasmussen	Dec 2014
NCT01744236	SAFEGUARD	SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies	P4	completed	70	Amsterdam UMC, location VUmc	Apr 2013
NCT02584582	ALFA-1	The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate	P2/P3	unknown	10	Hvidovre University Hospital	Jul 2015
NCT01595789	AddHope2	The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes	P4	completed	41	Haugaard, Steen Bendix, M.D., DMSc	May 2012
NCT01836523	ADJUNCT ONE™	The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes	P3	completed	1,398	Novo Nordisk A/S	Nov 2013
NCT01937598		Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D	P3	completed	16	Michael A. Nauck	Aug 2013
NCT01907854	LIRA-SWITCH™	Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin	P4	completed	407	Novo Nordisk A/S	Dec 2013
NCT02109315	DIAB-01	Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.	P1	withdrawn	0	Anna Cruceta	May 2014
NCT02098395	ADJUNCT TWO™	The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes	P3	completed	835	Novo Nordisk A/S	May 2014
NCT02100475	DUAL™	A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification	P3	completed	31	Novo Nordisk A/S	Apr 2014
NCT01787916	LIDO	52 Week Trial of Liraglutide in Type 1 Diabetes	P4	completed	15	CHU de Quebec-Universite Laval	Apr 2013
NCT02089256		Effect of Repeated Administration of Liraglutide on Insulinogenic Indices	P4	completed	10	University of Tartu	Jun 2014
NCT02315001	LIONESS	Liraglutide to Improve corONary Haemodynamics During Exercise streSS	P2	completed	26	King's College London	Jan 2014
NCT01272219		Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes	P3	completed	3,731	Novo Nordisk A/S	Jun 2011
NCT01733758	T2DM	A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)	P3	completed	494	GlaxoSmithKline	Feb 2013
NCT01612468		Liraglutide in Type 1 Diabetes	P4	completed	100	Steno Diabetes Center Copenhagen	Jun 2012
NCT01782261		Incretin Effect on the Immunological Phenotype	P2	completed	15	Medical University of Graz	Feb 2012
NCT01755416		Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting	P2	completed	18	Albert Einstein College of Medicine	Jan 2013
NCT01739049		Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese	P4	completed	42	Universiti Kebangsaan Malaysia Medical Centre	Nov 2012
NCT01363609	LIBRA	Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes	N/A	completed	50	Amsterdam UMC, location VUmc	Oct 2011
NCT02057172		Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes	P2	completed	254	Hanmi Pharmaceutical Company Limited	Jan 2014
NCT01870297		A Study of LY3025876 in Participants With Diabetes	P1	completed	72	Eli Lilly and Company	Jun 2013
NCT01593137	ADELANTE	A Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes	P4	withdrawn	0	Fundación Fernández-Cruz	May 2012
NCT01722266		Liraglutide in the Treatment of Type 1 Diabetes Mellitus	P3	completed	72	University at Buffalo	Nov 2012
NCT02008682		The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes	P4	completed	368	Novo Nordisk A/S	Dec 2013
NCT01973231	LIRA-LIXI™	Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes	P4	completed	404	Novo Nordisk A/S	Oct 2013
NCT01952145	DUAL™ V	A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus	P3	completed	557	Novo Nordisk A/S	Sep 2013
NCT02092896	T1DMLIRA	Liraglutide as add-on to Insulin in Type 1 Diabetes	P3	completed	40	Hvidovre University Hospital	Mar 2013
NCT01484262		Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2	—	completed	1,344	Novo Nordisk A/S	Nov 2011
NCT01982630	MK-8521-003	Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)	P1	completed	87	Merck Sharp & Dohme LLC	Nov 2013
NCT02207348		Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors	P1	completed	24	Novo Nordisk A/S	Aug 2014
NCT01785043	LAED001	Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users	P4	completed	13	Anna Cruceta	Mar 2013
NCT01917656	LIRA-Ramadan™	Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes	P4	completed	343	Novo Nordisk A/S	Jan 2014
NCT02077946		A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden	—	completed	1,059	Novo Nordisk A/S	Feb 2014
NCT02113332		Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections	P2	completed	124	Vastra Gotaland Region	Jan 2013
NCT01499108	Liratime	Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes	P4	completed	32	Peter Rossing	Aug 2012
NCT01237119	LEAN	Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis	P2	completed	52	University of Birmingham	Aug 2010
NCT02187250		PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome	P4	completed	45	University Medical Centre Ljubljana	Mar 2014
NCT01890993		Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe	—	completed	952	Novo Nordisk A/S	Aug 2013
NCT01597531		Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding	P4	terminated	1	East Carolina University	Jun 2012
NCT01399645	LIRAINS	Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes	P2	completed	35	Centre hospitalier de l'Université de Montréal (CHUM)	May 2011
NCT01789086		A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years	P1	completed	21	Novo Nordisk A/S	Feb 2013
NCT01558271		A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus	P3	completed	492	Eli Lilly and Company	Mar 2012
NCT01562678		Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI	P4	completed	28	Beth Israel Deaconess Medical Center	Mar 2012
NCT01392898	ELEGANT	Liraglutide and Insulin Therapy in Patients With Type 2 Diabetes	N/A	unknown	50	Radboud University Medical Center	Feb 2012
NCT01270789	LIBRA	LIraglutide and Beta-cell RepAir (LIBRA) Study	P3	completed	63	Mount Sinai Hospital, Canada	Jan 2011
NCT01755572	BOLT	Blood Pressure Outcomes With Liraglutide Therapy	P4	completed	22	Mount Sinai Hospital, Canada	Jan 2013
NCT01676116	DUAL™ III	The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy	P3	completed	438	Novo Nordisk A/S	Aug 2012
NCT01664676		Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients	P4	completed	11	University of Aarhus	Dec 2012
NCT02016846		Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes	P3	unknown	36	Rabin Medical Center	Jan 2014
NCT01664247		The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification	P3	completed	346	Novo Nordisk A/S	Oct 2012
NCT01550653		Liraglutide Effects on Memory in Healthy Subjects	P1	completed	40	University of Luebeck	May 2012
NCT01916174		A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects	P1	completed	50	Novo Nordisk A/S	Aug 2013
NCT01638260		GLP-1 and Non-exercise Activity Thermogenesis in RHZ	P4	terminated	22	Maastricht University Medical Center	Oct 2012
NCT01624259	AWARD-6	A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes	P3	completed	599	Eli Lilly and Company	Jun 2012
NCT01654120		Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics	P4	completed	37	Mountain Diabetes and Endocrine Center	Dec 2011
NCT01226966	EVIDENCE	Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes	—	completed	3,152	Novo Nordisk A/S	Sep 2010
NCT01617434		The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes	P3	completed	451	Novo Nordisk A/S	Sep 2012
NCT01394341		Liraglutide Treatment to Patients With Severe Renal Insufficiency	P4	completed	40	Bo Feldt-Rasmussen	Sep 2011
NCT01618162	DUAL™IV	The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy	P3	completed	435	Novo Nordisk A/S	Aug 2012
NCT01725126		To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes	P2	completed	53	GlaxoSmithKline	Feb 2013
NCT01610934	MODY	The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)	P2/P3	completed	15	University Hospital, Gentofte, Copenhagen	Aug 2012
NCT01620489		Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment	P3	completed	279	Novo Nordisk A/S	Jun 2012
NCT01596504		Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin	P2	completed	142	Sanofi	May 2012
NCT01345734	Lead-Ph	Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes	—	completed	1,056	Novo Nordisk A/S	Sep 2011
NCT01299012		Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus	—	completed	30	University at Buffalo	Oct 2010
NCT01557166		Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea	P3	completed	359	Novo Nordisk A/S	Jun 2012
NCT01206101		Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation	P2	terminated	3	Novo Nordisk A/S	Mar 2012
NCT01460069	GLP	The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis	N/A	completed	20	Annesofie Faurschou	Oct 2011
NCT01469351		Identifying Potential Effects of Liraglutide on Degenerative Changes	N/A	completed	34	University of Aarhus	Jan 2012
NCT01911468		Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin	P4	completed	36	University Medical Centre Ljubljana	Nov 2011
NCT01899430		Polycystic Ovary Syndrome and Liraglutide	P4	completed	32	University Medical Centre Ljubljana	Nov 2011
NCT01512108		Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone	P3	completed	363	Novo Nordisk A/S	Jan 2012
NCT01542242		Liraglutide Use in Prader-Willi Syndrome	P4	terminated	1	Vancouver General Hospital	Feb 2012
NCT01288326	ROOTS	Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes	—	completed	254	Novo Nordisk A/S	Feb 2011
NCT01117350	EAGLE	Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure	P4	completed	978	Sanofi	Jul 2010
NCT01572740		Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes	P3	completed	257	Novo Nordisk A/S	Apr 2012
NCT01272232		Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes	P3	completed	846	Novo Nordisk A/S	Jun 2011
NCT01451905		GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis	N/A	unknown	12	University Hospital, Gentofte, Copenhagen	Aug 2011
NCT02292290	T4R	Trial for People With Established Type 2 Diabetes During Ramadan	P4	completed	99	University of Leicester	Apr 2011
NCT01784965		Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.	P3	completed	69	Stanford University	Dec 2009
NCT01336023	DUAL™ I	Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes	P3	completed	1,663	Novo Nordisk A/S	May 2011
NCT01518101	PREFER	Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications	P4	completed	62	Novartis Pharmaceuticals	Jan 2012
NCT01392573	DUAL™ II	A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes	P3	completed	413	Novo Nordisk A/S	Nov 2011
NCT01536665		The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes	P1	completed	45	Novo Nordisk A/S	Feb 2012
NCT01388361	BEGIN™	Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin	P3	completed	413	Novo Nordisk A/S	Sep 2011
NCT02721888	LIRA-NAFLD/LIP	Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism	P4	terminated	127	Centre Hospitalier Universitaire Dijon	Jul 2012
NCT01592279		GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients	P4	unknown	124	Hadassah Medical Organization	Jun 2012
NCT01212133	Lead-In	A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India	—	completed	1,386	Novo Nordisk A/S	Nov 2010
NCT01473953		Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects	P1	completed	31	Novo Nordisk A/S	Oct 2011
NCT01695109		The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy Volunteers	P4	completed	16	Medical University of Vienna	Nov 2010
NCT01296412	MK-0431-403	Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)	P3	completed	653	Merck Sharp & Dohme LLC	Mar 2011
NCT01516476		Study of RO6807952 in Patients With Diabetes Mellitus Type 2	P2	terminated	2	Hoffmann-La Roche	Nov 2011
NCT01599338		Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients	N/A	completed	30	Centre Hospitalier Universitaire Dijon	Jan 2011
NCT01128894		A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.	P3	completed	841	GlaxoSmithKline	May 2010
NCT00943501		Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes	P1	completed	21	Novo Nordisk A/S	Nov 2009
NCT01373450	MK-0000-222	Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)	P1	completed	12	Merck Sharp & Dohme LLC	Jun 2011
NCT00978393		A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers	P1	completed	49	Novo Nordisk A/S	Sep 2009
NCT01319240	A3	Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects	P1	completed	24	Novo Nordisk A/S	Mar 2011
NCT01029886		Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes	P3	completed	912	AstraZeneca	Jan 2010
NCT00993304		A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics	P1	completed	20	Novo Nordisk A/S	Oct 2009
NCT01175473		Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes	P2	completed	148	Sanofi	Aug 2010
NCT00856986		The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes	P3	completed	987	Novo Nordisk A/S	Mar 2009
NCT00993720		Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes	P2/P3	completed	30	Hvidovre University Hospital	Oct 2009
NCT00781937		Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance	P3	completed	422	Novo Nordisk A/S	Oct 2008
NCT00700817		The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus	P3	completed	665	Novo Nordisk A/S	Jun 2008
NCT00620282		The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus	P3	completed	49	Novo Nordisk A/S	Feb 2008
NCT00983021		Safety and Tolerability of NN9068 in Healthy Male Volunteers	P1	completed	24	Novo Nordisk A/S	Sep 2009
NCT00873223		Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir	P1	completed	33	Novo Nordisk A/S	Mar 2009
NCT00518882	LEAD-6	Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes	P3	completed	467	Novo Nordisk A/S	Aug 2007
NCT00422058		The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes	P2	completed	564	Novo Nordisk A/S	Jan 2007
NCT00614120		Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes	P3	completed	929	Novo Nordisk A/S	Jan 2008
NCT00696657		A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide	P2	completed	415	Novo Nordisk A/S	Jun 2008
NCT00761540		To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo	P1	completed	37	Novo Nordisk A/S	Oct 2008
NCT00318461	LEAD-2	To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together	P3	completed	1,091	Novo Nordisk A/S	May 2006
NCT00294723	LEAD-3	To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c	P3	terminated	746	Novo Nordisk A/S	Feb 2006
NCT00393718		Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes	P3	completed	400	Novo Nordisk A/S	Nov 2006
NCT00395746	SU	Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes	P3	completed	264	Novo Nordisk A/S	Oct 2006
NCT01511692		Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes	P1	completed	43	Novo Nordisk A/S	Nov 2005
NCT00333151	LEAD-4	Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes	P3	completed	576	Novo Nordisk A/S	May 2006
NCT01513525		Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers	P1	completed	21	Novo Nordisk A/S	Feb 2007
NCT01517555		Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes	P1	completed	18	Novo Nordisk A/S	Oct 2006
NCT00318422	LEAD-1	Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes	P3	completed	1,041	Novo Nordisk A/S	May 2006
NCT01515553		Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers	P1	completed	22	Novo Nordisk A/S	Jan 2007
NCT01508858		Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women	P1	completed	21	Novo Nordisk A/S	Nov 2006
NCT00331851	LEAD-5	Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes	P3	completed	584	Novo Nordisk A/S	May 2006
NCT01518166		Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH	P1	completed	70	Novo Nordisk A/S	May 2006
NCT01517568		Metabolism and Excretion of Liraglutide in Healthy Male Volunteers	P1	completed	7	Novo Nordisk A/S	Nov 2006
NCT01516255		Effect of Liraglutide on Heart Frequency in Healthy Volunteers	P1	completed	64	Novo Nordisk A/S	Jul 2006
NCT01515579		Comparison of Two Liraglutide Formulations in Healthy Subjects	P1	completed	22	Novo Nordisk A/S	Apr 2006
NCT01507389		Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function	P1	completed	24	Novo Nordisk A/S	Mar 2006
NCT00154414		Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes	P2	completed	226	Novo Nordisk A/S	Jan 2005
NCT01515592		Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers	P1	completed	24	Novo Nordisk A/S	Jan 2006
NCT01508806		Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function	P1	completed	30	Novo Nordisk A/S	Aug 2005
NCT00154401		Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes	P2	completed	177	Novo Nordisk A/S	Jan 2005
NCT01514487		Comparison of Three Liraglutide Formulations in Healthy Volunteers	P1	completed	24	Novo Nordisk A/S	Jan 2005
NCT01508897		Comparison of Two Liraglutide Formulations in Healthy Volunteers	P1	completed	22	Novo Nordisk A/S	May 2004
NCT01507337		Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers	P1	completed	32	Novo Nordisk A/S	Apr 2004
NCT01615978		Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes	P1	completed	15	Novo Nordisk A/S	Dec 2003
NCT01620476		Safety and Tolerability of Liraglutide in Healthy Japanese Volunteers	P1	completed	24	Novo Nordisk A/S	Sep 2003
NCT01620463		Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers	P1	completed	32	Novo Nordisk A/S	Dec 2002
NCT01511172		Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes	P2	completed	145	Novo Nordisk A/S	Aug 2002
NCT01508949		Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes	P2	completed	35	Novo Nordisk A/S	Jun 2001
NCT01508923		Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes	P2	completed	17	Novo Nordisk A/S	May 2001
NCT01511159		Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers	P1	completed	32	Novo Nordisk A/S	Oct 2001
NCT01509742		Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes	P1	completed	19	Novo Nordisk A/S	Apr 2001
NCT01511185		Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group	P1	completed	20	Novo Nordisk A/S	Feb 2001
NCT01511198		Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent	P2	completed	223	Novo Nordisk A/S	Feb 2001
NCT01509755		Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes	P2	completed	196	Novo Nordisk A/S	Oct 2000
NCT01507311		Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes	P1	completed	11	Novo Nordisk A/S	Sep 1999
NCT01507272		Safety and Tolerability of Liraglutide in Healthy Male Volunteers	P1	completed	34	Novo Nordisk A/S	Mar 1999
NCT01507285		Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes	P1	completed	24	Novo Nordisk A/S	Aug 1999

Liraglutide clinical trials: frequently asked questions

How many Liraglutide clinical trials are there?: 408 Liraglutide clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 11 are actively recruiting participants. 306 are marked completed.
Are Liraglutide clinical trials recruiting in 2026?: Yes — 11 Liraglutide trials are actively recruiting in 2026, with 5 U.S. sites across 5 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Liraglutide being studied for?: Liraglutide is being studied for Diabetes, Diabetes Mellitus, Type 2, Obesity, Type 2 Diabetes, Type 2 Diabetes Mellitus and 173 more. The trials are grouped by indication on this page.
What phase is Liraglutide in?: Liraglutide clinical trials span 109 Phase 4, 101 Phase 3, 55 Phase 2, 60 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Liraglutide clinical trials?: The lead sponsor across the most Liraglutide trials is Novo Nordisk A/S, with 187 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Liraglutideas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.

Related pages on Hipa.ai:

Liraglutide overview Liraglutide evidence & publications